ANDAORALTABLET
Approved
Oct 2005
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
2
Mechanism of Action
Cyclobenzaprine hydrochloride relieves skeletal muscle spasm of local origin without interfering with muscle function. It is ineffective in muscle spasm due to central nervous system disease. Cyclobenzaprine reduced or abolished skeletal muscle hyperactivity in several animal models. Animal studies…
Clinical Trials (2)
A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants
Started Dec 2025
50 enrolled
PharmakokineticOpen LabelPhase 1
Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the Treatment of Chronic Migraine
Started Jul 2010
35 enrolled
Chronic Migraine